These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30771210)

  • 21. Diabetic microvascular complications and growth factors.
    Pfeiffer A; Schatz H
    Exp Clin Endocrinol Diabetes; 1995; 103(1):7-14. PubMed ID: 7621107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetic vascular complications.
    Cooper ME; Gilbert RE; Jerums G
    Clin Exp Pharmacol Physiol; 1997; 24(9-10):770-5. PubMed ID: 9315387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis.
    Rahman S; Rahman T; Ismail AA; Rashid AR
    Diabetes Obes Metab; 2007 Nov; 9(6):767-80. PubMed ID: 17924861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The role of glucose and reactive oxygen species in the development of vascular complications of diabetes mellitus].
    Ksiazek K; Wiśniewska J
    Przegl Lek; 2001; 58(10):915-8. PubMed ID: 11957818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperglycemia-associated alterations in cellular signaling and dysregulated mitochondrial bioenergetics in human metabolic disorders.
    Stefano GB; Challenger S; Kream RM
    Eur J Nutr; 2016 Dec; 55(8):2339-2345. PubMed ID: 27084094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications.
    Chawla D; Bansal S; Banerjee BD; Madhu SV; Kalra OP; Tripathi AK
    Microvasc Res; 2014 Sep; 95():1-6. PubMed ID: 24984291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Oxidative stress].
    Maeda Y; Inoguchi T
    Nihon Rinsho; 2010 May; 68(5):814-8. PubMed ID: 20446574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dermal microvessel density and maturity is closely associated with atherogenic dyslipidemia and accumulation of advanced glycation end products in adult patients with type 1 diabetes.
    Adamska A; Araszkiewicz A; Pilacinski S; Gandecka A; Grzelka A; Kowalska K; Malinska A; Nowicki M; Zozulinska-Ziolkiewicz D
    Microvasc Res; 2019 Jan; 121():46-51. PubMed ID: 30312628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incretin-Based Therapy for Prevention of Diabetic Vascular Complications.
    Mima A
    J Diabetes Res; 2016; 2016():1379274. PubMed ID: 26881236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular understanding of hyperglycemia's adverse effects for diabetic complications.
    Sheetz MJ; King GL
    JAMA; 2002 Nov; 288(20):2579-88. PubMed ID: 12444865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury.
    Soulis T; Thallas V; Youssef S; Gilbert RE; McWilliam BG; Murray-McIntosh RP; Cooper ME
    Diabetologia; 1997 Jun; 40(6):619-28. PubMed ID: 9222639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxidative stress and diabetic cardiovascular disorders: roles of mitochondria and NADPH oxidase.
    Shen GX
    Can J Physiol Pharmacol; 2010 Mar; 88(3):241-8. PubMed ID: 20393589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FOXO1 inhibition potentiates endothelial angiogenic functions in diabetes via suppression of ROCK1/Drp1-mediated mitochondrial fission.
    Shi Y; Fan S; Wang D; Huyan T; Chen J; Chen J; Su J; Li X; Wang Z; Xie S; Yun C; Li X; Tie L
    Biochim Biophys Acta Mol Basis Dis; 2018 Jul; 1864(7):2481-2494. PubMed ID: 29654945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Manifestations of cutaneous diabetic microangiopathy.
    Ngo BT; Hayes KD; DiMiao DJ; Srinivasan SK; Huerter CJ; Rendell MS
    Am J Clin Dermatol; 2005; 6(4):225-37. PubMed ID: 16060710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease.
    Cooper ME
    Am J Hypertens; 2004 Dec; 17(12 Pt 2):31S-38S. PubMed ID: 15607433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory.
    Yamagishi SI; Nakamura N; Matsui T
    J Diabetes; 2017 Feb; 9(2):141-148. PubMed ID: 27556881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tannins and vascular complications of Diabetes: An update.
    Laddha AP; Kulkarni YA
    Phytomedicine; 2019 Mar; 56():229-245. PubMed ID: 30668344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diabetic microangiopathy: pathology and current understanding of its pathogenesis.
    Yagihashi S; Wada R; Yamagishi S
    Verh Dtsch Ges Pathol; 2002; 86():91-100. PubMed ID: 12647356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic Contribution to the Development and Progression of Vascular Diabetic Complications.
    Rodriguez H; El-Osta A
    Antioxid Redox Signal; 2018 Oct; 29(11):1074-1091. PubMed ID: 29304555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The molecular basis of diabetic microangiopathy.
    Mokini Z; Chiarelli F
    Pediatr Endocrinol Rev; 2006 Dec-2007 Jan; 4(2):138-52. PubMed ID: 17342030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.